Skip to content
Subscriber Only

Idenix May Drop Delayed Hepatitis C Drug for New Versions

Idenix Pharmaceuticals Inc., a developer of hepatitis C drugs, may shelve experimental treatments currently on hold by U.S. regulators and focus on different versions, Chief Executive Officer Ron Renaud said.

The Food and Drug Administration is continuing to assess trials halted last year on two drugs, Cambridge, Massachusetts-based Idenix said today in a slide presentation released ahead of the company’s appearance at the JPMorgan Chase & Co. health-care conference in San Francisco.